Sumitomo Dainippon Pharma announces personnel changes
Toray Applies for Japanese Approval of Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5 µg and Notice Regarding Promotion Tie-up
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes Related to Officers and Other Key Positions
Sunovion Pharmaceuticals Inc. Announces Initiation of Phase 3 Clinical Trial Program for SUN-101/eFlow® (Glycopyrrolate) in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Posted Conference Call for Third Quarter Financial Results for FY2014 [Webcast]
"Corporate profile" An English version and a Japanese version are updated.
A Message from the President
Board of Directors and Executive Officers